OnKure Therapeutics (OKUR) & Its Peers Critical Comparison

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,045 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare OnKure Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, risk and earnings.

Volatility & Risk

OnKure Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ peers have a beta of 1.00, indicating that their average share price is 0% more volatile than the S&P 500.

Profitability

This table compares OnKure Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,610.73%	-267.68%	-30.94%

Earnings and Valuation

This table compares OnKure Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.36
OnKure Therapeutics Competitors	$2.17 billion	$150.70 million	-5.38

OnKure Therapeutics’ peers have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for OnKure Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7552	20789	48373	1185	2.55

OnKure Therapeutics presently has a consensus price target of $37.50, indicating a potential upside of 125.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 74.41%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe OnKure Therapeutics is more favorable than its peers.

Institutional and Insider Ownership

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

OnKure Therapeutics beats its peers on 9 of the 13 factors compared.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.